Login to Your Account



IntraBiotics Receives FDA Nod To Proceed With Pivotal Trials

By Aaron Lorenzo


Monday, September 22, 2003
Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription